Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis

被引：0
作者：
Di Zhao
Hui Liu
Pingshuan Dong
机构：
[1] The First Affiliated Hospital,Division of Hypertension
[2] and College of Clinical Medicine of Henan University of Science and Technology,Division of Endocrinology
[3] Luoyang Central Hospital Affiliated to Zhengzhou University,Division of Cardiology
[4] The First Affiliated Hospital,undefined
[5] and College of Clinical Medicine of Henan University of Science and Technology,undefined
来源：
Irish Journal of Medical Science (1971 -) | 2019年 / 188卷
关键词：
Azilsartan; Essential hypertension; Meta-analysis; Olmesartan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：481 / 488
页数：7
相关论文
共 212 条
[31]  
Kajiya T(2015)The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling J Renin-Angiotensin-Aldosterone Syst 16 1245-21
[32]  
Kalikar M(2015)Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased byolmesartan, an angiotensin II receptor blocker Am J Hypertens 28 15-164
[33]  
Nivangune KS(2015)Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan J Renin-Angiotensin-Aldosterone Syst 16 159-232
[34]  
Dakhale GN(2016)Olmesartan-induced enteropathy Methodist Debakey Cardiovasc J 12 230-undefined
[35]  
Bajait CS(undefined)undefined undefined undefined undefined-undefined
[36]  
Sontakke SD(undefined)undefined undefined undefined undefined-undefined
[37]  
Motghare VM(undefined)undefined undefined undefined undefined-undefined
[38]  
Budania R(undefined)undefined undefined undefined undefined-undefined
[39]  
Kario K(undefined)undefined undefined undefined undefined-undefined
[40]  
Saito I(undefined)undefined undefined undefined undefined-undefined
12345678910